Dec 22, 2009 by Brian Orelli, PhDThis Acquisition Is Icy HotIcy price, but Chattem may still be a good buy for sanofi-aventis.
Dec 18, 2009 by Brian Orelli, PhDBuy a Company, Get the Plant for FreeIt's certainly easier than building it yourself.
Dec 18, 2009 by Brian Orelli, PhD2009: The Year Pharma Learned to Love ItselfNarcissism isn't always healthy.
Dec 18, 2009 by Brian Orelli, PhDSwine Flu Just Isn't Bringing Home the BaconAs much hype as the avian flu and headed in the same direction.
Dec 17, 2009 by Brian Orelli, PhDThis Acquisition Hears, Smells, and Tastes Soooo GoodJohnson & Johnson picks up an ear, nose, and throat medical device maker.
Dec 16, 2009 by Brian Orelli, PhDGilead's Phase 3 Train WreckGilead Sciences' darusentan looked so promising.
Dec 16, 2009 by Brian Orelli, PhDNo Holiday Goodwill Twixt Biogen and FacetBiogen and Facet are still at it, as their nasty takeover fight continues.
Dec 15, 2009 by Brian Orelli, PhDIt's Nice to Have Friends With CashArray hits up Amgen for some much-needed cash.
Dec 15, 2009 by Brian Orelli, PhDForget the Higher DosesElan has to drop the highest dose of an Alzheimer's drug. Again.
Dec 14, 2009 by Brian Orelli, PhDFinally Released From an Extended ReviewThe FDA finally approves extended-release Zyprexa.
Dec 11, 2009 by Brian Orelli, PhDGilead Gets the Experts on Its SideAn advisory committee says yes after the FDA said no.
Dec 11, 2009 by Brian Orelli, PhDRoche and Biogen's Blockbuster Making Good ProgressRoche and Biogen move their potential blockbuster through the clinical trial maze.
Dec 10, 2009 by Brian Orelli, PhDThe Public Option Is Dead. Again. Maybe.So why haven't health insurers' stocks rebounded?
Dec 9, 2009 by Brian Orelli, PhDWelcome to Club Biogeneric, Pfizer!The megadrugmaker jumps on the biogeneric bandwagon.
Dec 9, 2009 by Brian Orelli, PhDRising From the ASHesDecoding the data from the blood cancer meeting.
Dec 8, 2009 by Brian Orelli, PhDEarly and Often: A Drug Investor's DreamThere's no better way to increase sales.
